{"success":true,"data":{"pressRelease":{"id":"145169","rtpr_id":"nGNE6D9cZz-20260916","ticker":"CUPR","exchange":"NASDAQ","all_tickers":["CUPR"],"title":" Cuprina Holdings (Cayman) Limited Announces Pricing of $4.97 million Public Offering","author":"Globe Newswire","published_at":"2026-09-16T12:30:00.273Z","article_body":"SINGAPORE, Sept. 16, 2026 (GLOBE NEWSWIRE) -- Cuprina Holdings (Cayman)\nLimited (Nasdaq: CUPR) (“Cuprina” or “the Company”), a biomedical\ncompany developing and marketing products for the chronic wounds, infertility,\nmedical waste recycling, and cosmeceuticals sectors, today announced the\npricing of its firm commitment public offering of an aggregate 4,322,489\nshares of its Class A Ordinary Shares (“the Offering”), all of which are\nbeing offered by CUPR at a public offering price of $1.15 per share (“the\nOffering Price”), for a total of approximately $4.97 million of gross\nproceeds to the Company, before deducting underwriting discounts and offering\nexpenses.\n\nThe Company has granted the underwriter a 45-day option to purchase up to an\nadditional 648,373 shares of its Class A Ordinary Shares at the Offering\nPrice, representing 15% of the Class A Ordinary Shares sold in the Offering\n(“the Over-allotment”). Assuming that the Over-allotment is exercised, the\nCompany is expected to receive gross proceeds amounting to approximately $5.72\nmillion, before deducting underwriting discounts and commissions and estimated\noffering expenses.\n\nThe Offering is expected to close on or about September 17, 2026, subject to\nthe satisfaction of customary closing conditions.\n\nR. F. Lafferty & Co., Inc. (“R. F. Lafferty”), acted as the sole\nbook-running manager for the Offering. Loeb & Loeb LLP, Lee & Lee, Harney\nWestwood & Riegels Singapore LLP are acting as U.S., Singapore and Cayman\nIslands legal counsels to the Company, respectively, and Ellenoff Grossman &\nSchole LLP is acting as U.S. legal counsel to R. F. Lafferty for the Offering.\n\nThe Offering is being conducted pursuant to the Company’s Registration\nStatement on Form F-1 (File No: 333-297299) previously filed with and\nsubsequently declared effective by the U.S. Securities and Exchange Commission\n(“SEC”) on September 15, 2026. The Offering is being made only by means of\na prospectus. Before you invest, you should read the prospectus and other\ndocuments the Company has filed or will file with the SEC for more information\nabout the Company and the Offering. Copies of the final prospectus related to\nthe Offering may be obtained, when available, from R. F. Lafferty & Co., Inc.,\n40 Wall Street, Suite 3602, New York, NY 10005; (212) 293-9090, or by email at\nofferings@rflafferty.com. In addition, a copy of the final prospectus, when\navailable, relating to the Offering may be obtained via the SEC’s website at\nwww.sec.gov.\n\nThis press release has been prepared for informational purposes only and shall\nnot constitute an offer to sell or the solicitation of an offer to buy any of\nthe Company’s securities, nor shall such securities be offered or sold in\nthe United States absent registration or an applicable exemption from\nregistration, nor shall there be any offer, solicitation or sale of these\nsecurities in any state or jurisdiction in which such offer, solicitation or\nsale would be unlawful prior to registration or qualification under the\nsecurities laws of any such state or other jurisdiction.\n\nAbout Cuprina Holdings (Cayman) Limited\n\nWe are a Singapore-based biomedical and biotechnology company that is\ndedicated to the development and commercialization of innovative products for\nthe management of chronic wounds, as well as operating in the infertility,\nmedical waste recycling, and health and beauty sectors. Our expertise in\nbiomedical research allows us to identify and utilize materials derived from\nnatural sources to develop wound care products in the form of medical devices\nwhich meet international standards. For more information, please visit\nhttps:// www.cuprina.com.\n\nFORWARD-LOOKING STATEMENTS\n\nCertain statements contained in this press release about future expectations,\nplans and prospects, as well as any other statements regarding matters that\nare not historical facts, may constitute “forward-looking statements”\nwithin the meaning of the Private Securities Litigation Reform Act of 1995.\nThese statements include, but are not limited to, statements relating to the\nexpected completion, timing and gross proceeds of the offering. The words\n“anticipate,” “believe,” “continue,” “could,” “estimate,”\n“expect,” “intend,” “may,” “plan,” “potential,”\n“predict,” “project,” “should,” “target,” “will,”\n“would” and similar expressions are intended to identify forward-looking\nstatements, although not all forward-looking statements contain these\nidentifying words. Actual results may differ materially from those indicated\nby such forward-looking statements as a result of various important factors,\nincluding: the uncertainties related to market conditions and the completion\nof the public offering on the anticipated terms or at all, and other factors\ndiscussed in the “Risk Factors” section of the preliminary prospectus\nfiled with the SEC. For these reasons, among others, investors are cautioned\nnot to place undue reliance upon any forward-looking statements in this press\nrelease. Any forward-looking statements contained in this press release speak\nonly as of the date hereof, and Cuprina Holdings (Cayman) Limited specifically\ndisclaims any obligation to update any forward-looking statement, whether as a\nresult of new information, future events or otherwise, except as required by\nlaw.\n\nCuprina Holdings (Cayman) Limited Investor Contact\n\nInvestor Relations\nc/o Blk 1090 Lower Delta Road #06-08\nSingapore 169201\n+65 8512 7275\nEmail: ir@cuprina.com.sg","article_body_html":"","raw_payload":{"data":{"id":"nGNE6D9cZz-20260916","title":" Cuprina Holdings (Cayman) Limited Announces Pricing of $4.97 million Public Offering","author":"Globe Newswire","ticker":"CUPR","created":"2026-09-16T12:30:00.273Z","tickers":["CUPR"],"exchange":"NASDAQ","article_body":"SINGAPORE, Sept. 16, 2026 (GLOBE NEWSWIRE) -- Cuprina Holdings (Cayman)\nLimited (Nasdaq: CUPR) (“Cuprina” or “the Company”), a biomedical\ncompany developing and marketing products for the chronic wounds, infertility,\nmedical waste recycling, and cosmeceuticals sectors, today announced the\npricing of its firm commitment public offering of an aggregate 4,322,489\nshares of its Class A Ordinary Shares (“the Offering”), all of which are\nbeing offered by CUPR at a public offering price of $1.15 per share (“the\nOffering Price”), for a total of approximately $4.97 million of gross\nproceeds to the Company, before deducting underwriting discounts and offering\nexpenses.\n\nThe Company has granted the underwriter a 45-day option to purchase up to an\nadditional 648,373 shares of its Class A Ordinary Shares at the Offering\nPrice, representing 15% of the Class A Ordinary Shares sold in the Offering\n(“the Over-allotment”). Assuming that the Over-allotment is exercised, the\nCompany is expected to receive gross proceeds amounting to approximately $5.72\nmillion, before deducting underwriting discounts and commissions and estimated\noffering expenses.\n\nThe Offering is expected to close on or about September 17, 2026, subject to\nthe satisfaction of customary closing conditions.\n\nR. F. Lafferty & Co., Inc. (“R. F. Lafferty”), acted as the sole\nbook-running manager for the Offering. Loeb & Loeb LLP, Lee & Lee, Harney\nWestwood & Riegels Singapore LLP are acting as U.S., Singapore and Cayman\nIslands legal counsels to the Company, respectively, and Ellenoff Grossman &\nSchole LLP is acting as U.S. legal counsel to R. F. Lafferty for the Offering.\n\nThe Offering is being conducted pursuant to the Company’s Registration\nStatement on Form F-1 (File No: 333-297299) previously filed with and\nsubsequently declared effective by the U.S. Securities and Exchange Commission\n(“SEC”) on September 15, 2026. The Offering is being made only by means of\na prospectus. Before you invest, you should read the prospectus and other\ndocuments the Company has filed or will file with the SEC for more information\nabout the Company and the Offering. Copies of the final prospectus related to\nthe Offering may be obtained, when available, from R. F. Lafferty & Co., Inc.,\n40 Wall Street, Suite 3602, New York, NY 10005; (212) 293-9090, or by email at\nofferings@rflafferty.com. In addition, a copy of the final prospectus, when\navailable, relating to the Offering may be obtained via the SEC’s website at\nwww.sec.gov.\n\nThis press release has been prepared for informational purposes only and shall\nnot constitute an offer to sell or the solicitation of an offer to buy any of\nthe Company’s securities, nor shall such securities be offered or sold in\nthe United States absent registration or an applicable exemption from\nregistration, nor shall there be any offer, solicitation or sale of these\nsecurities in any state or jurisdiction in which such offer, solicitation or\nsale would be unlawful prior to registration or qualification under the\nsecurities laws of any such state or other jurisdiction.\n\nAbout Cuprina Holdings (Cayman) Limited\n\nWe are a Singapore-based biomedical and biotechnology company that is\ndedicated to the development and commercialization of innovative products for\nthe management of chronic wounds, as well as operating in the infertility,\nmedical waste recycling, and health and beauty sectors. Our expertise in\nbiomedical research allows us to identify and utilize materials derived from\nnatural sources to develop wound care products in the form of medical devices\nwhich meet international standards. For more information, please visit\nhttps:// www.cuprina.com.\n\nFORWARD-LOOKING STATEMENTS\n\nCertain statements contained in this press release about future expectations,\nplans and prospects, as well as any other statements regarding matters that\nare not historical facts, may constitute “forward-looking statements”\nwithin the meaning of the Private Securities Litigation Reform Act of 1995.\nThese statements include, but are not limited to, statements relating to the\nexpected completion, timing and gross proceeds of the offering. The words\n“anticipate,” “believe,” “continue,” “could,” “estimate,”\n“expect,” “intend,” “may,” “plan,” “potential,”\n“predict,” “project,” “should,” “target,” “will,”\n“would” and similar expressions are intended to identify forward-looking\nstatements, although not all forward-looking statements contain these\nidentifying words. Actual results may differ materially from those indicated\nby such forward-looking statements as a result of various important factors,\nincluding: the uncertainties related to market conditions and the completion\nof the public offering on the anticipated terms or at all, and other factors\ndiscussed in the “Risk Factors” section of the preliminary prospectus\nfiled with the SEC. For these reasons, among others, investors are cautioned\nnot to place undue reliance upon any forward-looking statements in this press\nrelease. Any forward-looking statements contained in this press release speak\nonly as of the date hereof, and Cuprina Holdings (Cayman) Limited specifically\ndisclaims any obligation to update any forward-looking statement, whether as a\nresult of new information, future events or otherwise, except as required by\nlaw.\n\nCuprina Holdings (Cayman) Limited Investor Contact\n\nInvestor Relations\nc/o Blk 1090 Lower Delta Road #06-08\nSingapore 169201\n+65 8512 7275\nEmail: ir@cuprina.com.sg"},"type":"article","timestamp":"2026-09-16T12:30:00.572975881Z","server_sent_at_ms":1789561800572},"received_at":"2026-09-16T12:30:00.631Z","source_url":null},"analysis":{"id":"133993","press_release_id":"145169","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":["Offering priced at $1.15/share — penny-stock-level pricing for a Nasdaq-listed issuer","Use of proceeds not disclosed in the release","Over-allotment could add a further 648,373 shares (~15% more) to shareholder dilution"],"eventType":"offering","narrative":"Cuprina Holdings (Cayman) Limited priced a firm commitment public offering of 4,322,489 Class A ordinary shares at $1.15 per share, for gross proceeds of approximately $4.97 million before underwriting discounts and expenses.\n\nThe underwriter holds a 45-day option to purchase up to 648,373 additional shares, representing 15% of the deal; full exercise would lift gross proceeds to approximately $5.72 million.\n\nR. F. Lafferty & Co. is sole book-running manager, and the offering is expected to close on or about September 17, 2026, under an F-1 registration statement the SEC declared effective on September 15, 2026.","sentiment":"bearish","agentHooks":{"shouldPost":false,"suggestedAngle":"Micro-cap biomedical raise at $1.15/share — dilution watch into the September 17 close."},"keyFigures":{"dealValueUsd":4970000,"offeringPrice":1.15,"sharesOffered":4322489,"customDimensions":{"over_allotment_shares":648373,"over_allotment_option_days":45,"over_allotment_percent_of_deal":"15%","gross_proceeds_with_overallotment":5720000}},"namedEntities":{"people":[],"products":[],"companies":[{"name":"Cuprina Holdings (Cayman) Limited","ticker":"CUPR","relationship":"issuer"},{"name":"R. F. Lafferty & Co., Inc.","relationship":"sole book-running manager (underwriter)"},{"name":"Loeb & Loeb LLP","relationship":"U.S. legal counsel to the company"},{"name":"Lee & Lee","relationship":"Singapore legal counsel to the company"},{"name":"Harney Westwood & Riegels Singapore LLP","relationship":"Cayman Islands legal counsel to the company"},{"name":"Ellenoff Grossman & Schole LLP","relationship":"U.S. legal counsel to the underwriter"}],"dollarAmounts":[{"amount":"$4.97 million","context":"gross proceeds of the public offering before underwriting discounts and expenses"},{"amount":"$1.15","context":"public offering price per Class A ordinary share"},{"amount":"$5.72 million","context":"expected gross proceeds if the over-allotment is exercised in full"}]},"materialImpact":{"score":3,"reasoning":"Dilutive firm-commitment offering of 4,322,489 shares at $1.15/share raising only ~$4.97M gross for a micro-cap biomedical issuer, with a 15% over-allotment that could extend dilution. Material to shareholders, but the small absolute deal size and unstated use of proceeds keep it below market-moving territory."},"tickerRelevance":{"others":[],"primary":"CUPR"},"globalImportance":18,"audienceRelevance":12,"eventTypeSecondary":["dilution"],"importanceComponents":{"tickerTier":"micro-cap","eventGravity":"dilutive public offering ~$5M gross","offeringSizeUsd":4970000,"householdBrandBoost":0,"marketCapAdjustment":"share count not disclosed; dilution percentage unknown","retailFavoriteBoost":0}},"event_type":"offering","event_type_secondary":["dilution"],"sentiment":"bearish","material_impact_score":3,"narrative":"Cuprina Holdings (Cayman) Limited priced a firm commitment public offering of 4,322,489 Class A ordinary shares at $1.15 per share, for gross proceeds of approximately $4.97 million before underwriting discounts and expenses.\n\nThe underwriter holds a 45-day option to purchase up to 648,373 additional shares, representing 15% of the deal; full exercise would lift gross proceeds to approximately $5.72 million.\n\nR. F. Lafferty & Co. is sole book-running manager, and the offering is expected to close on or about September 17, 2026, under an F-1 registration statement the SEC declared effective on September 15, 2026.","key_figures":{"dealValueUsd":4970000,"offeringPrice":1.15,"sharesOffered":4322489,"customDimensions":{"over_allotment_shares":648373,"over_allotment_option_days":45,"over_allotment_percent_of_deal":"15%","gross_proceeds_with_overallotment":5720000}},"named_entities":{"people":[],"products":[],"companies":[{"name":"Cuprina Holdings (Cayman) Limited","ticker":"CUPR","relationship":"issuer"},{"name":"R. F. Lafferty & Co., Inc.","relationship":"sole book-running manager (underwriter)"},{"name":"Loeb & Loeb LLP","relationship":"U.S. legal counsel to the company"},{"name":"Lee & Lee","relationship":"Singapore legal counsel to the company"},{"name":"Harney Westwood & Riegels Singapore LLP","relationship":"Cayman Islands legal counsel to the company"},{"name":"Ellenoff Grossman & Schole LLP","relationship":"U.S. legal counsel to the underwriter"}],"dollarAmounts":[{"amount":"$4.97 million","context":"gross proceeds of the public offering before underwriting discounts and expenses"},{"amount":"$1.15","context":"public offering price per Class A ordinary share"},{"amount":"$5.72 million","context":"expected gross proceeds if the over-allotment is exercised in full"}]},"model_name":"glm-5.3-flash","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-09-16T12:30:31.344Z","global_importance":18,"audience_relevance":12,"importance_components":{"tickerTier":"micro-cap","eventGravity":"dilutive public offering ~$5M gross","offeringSizeUsd":4970000,"householdBrandBoost":0,"marketCapAdjustment":"share count not disclosed; dilution percentage unknown","retailFavoriteBoost":0}},"durationMs":30703,"modelName":"glm-5.3-flash"}}